Sirolimus-eluting versus paclitaxel-eluting stents: Are there differences in reality?

Cardiology International

Volumn 8, Issue 1, 2007, Pages 17-25

  Cook, S ^a   Meier, B ^a   Windecker, Stephan ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; METAL; PACLITAXEL; POLYMER; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; BLOOD VESSEL INJURY; CELL PROLIFERATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ELUTING STENT; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART DEATH; HEART INFARCTION; HUMAN; HYPERPLASIA; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; REVIEW; SMOOTH MUSCLE FIBER; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 34247889937     PISSN: 14688581     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701-706.
2. Serruys PW, De Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. New Engl J Med 1994; 331: 489-495.
3. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. New Engl J Med 1994; 331: 496-501.
4. Kimura T, Yokoi H, Nakagawa Y et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996; 334: 561-566.
5. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med 2003; 138: 777-786.
6. Al Suwaidi J, Berger PB, Holmes DR, Jr. Coronary artery stents. JAMA 2000; 284: 1828-1836.
7. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001; 104: 852-855.
8. Poon M, Badimon JJ, Fuster V. Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. Lancet 2002; 359: 619-622.
9. Axel DI, Kunert W, Goggelmann C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-645.
10. Farb A, Heller PF, Shroff S et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001; 104: 473-479.
11. Stone GW, Ellis SG, Cannon L et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294: 1215-1223.
12. Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221-231.
13. Colombo A, Drzewiecki J, Banning A et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788-794.
14. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerekens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2002; 107: 38-42.
15. Sabate M, Jimenez-Quevedo P, Angiolillo DJ et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005; 112: 2175-2183.
16. Ardissino D, Cavallini C, Bramucci E et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004; 292: 2727-2734.
17. Schampaert E, Cohen EA, Schluter M et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43: 1110-1115.
18. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-1099.
19. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
20. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
21. Morice MC, Colombo A, Meier B et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006; 295: 895-904.
22. Kastrati A, Mehilli J, von Beckerath N et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005; 293: 165-171.
23. Windecker S, Remondino A, Eberli FR et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653-662.
24. Kaiser C, Brunner-La Rocca HP, Buser PT et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitaet Trial (BASKET). Lancet 2005; 366: 921-929.
25. Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 2005; 45: 308-311.
26. Dibra A, Kastrati A, Mehilli J et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-670.
27. de Lezo J, Medina A, Pan M et al. Drug-eluting stents for complex lesions: randomized rapamycin versus paclitaxel CORPAL study. J Am Coll Cardiol 2005; 45(SupplA):75A
28. Zhang Q, Zhang RY, Zhang JS et al. One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease. Chin Med J (Engl) 2006; 119: 165-168.
29. Kim YH, Park SW, Lee SW et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 2006; 114: 2148-2153.
30. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schomig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006; 27: 260-266.
31. Galloe AM, Thuesen L, Kelbaek H et al. SORT OUT II: A prospective, multi-center, large-scale, randomized trial of paclizaxel- and sirolimus-eluting stents in "real-world" lesions: nine-month clinical results. Transcatheter Cardiovascular Therapeutics 2006; Late Breaking Clinical Trials.
32. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364: 583-591.
33. Stettler C, Allemann S, Egger M, Windecker S, Meier B, Diem P. Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart 2006; 92: 650-657.
34. Ong AT, Serruys PW, Aoki J et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005; 45: 1135-1141.
35. Mauri L, Orav EJ, Candia SC, Cutlip DE, Kuntz RE. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005; 112: 2833-2839.
36. Kastrati A, Dibra A, Eberle S et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005; 294: 819-825.